SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update
May 02 2022 - 8:41AM
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the
“
Company” or “
SciSparc”), today
announced that it has filed its annual report on Form 20-F for the
fiscal year ended December 31, 2021 with the U.S. Securities and
Exchange Commission (the “
SEC”).
Recent Corporate
Highlights:
-
Issued U.S. patent surrounding the Company’s core technology that
treats central nervous systems disorders
-
Recruited first patient in the Phase IIa clinical trial of SCI-110
in Alzheimer's disease
-
Advanced the Phase IIb clinical trial of SCI-110 in patients with
Tourette syndrome
-
Entered into a collaboration agreement with ClearMind Medicine Inc.
for the development of innovative psychedelic-based
pharmaceuticals
-
Entered into a JV agreement with MitoCare X targeting the discovery
of potential drugs for cancers and infectious diseases
Oz Adler, SciSparc's Chief Executive Officer,
commented, "2021 was a turnaround year for SciSparc. We
successfully up-listed to the Nasdaq stock exchange and raised
approximately $8 million from high quality investors.
Operationally, we expanded our IP protection in key territories and
advanced our programs in Tourette syndrome, Alzheimer's disease and
Agitation, Status Epilepticus and pain. In 2022, we plan on
continuing our advancement in our clinical and pre- clinical
programs and move closer towards developing and presenting
innovative therapies.”
The annual report, which contains the Company’s
audited consolidated financial statements, can be accessed on the
SEC website at http://www.sec.gov as well as via the
Company’s website at https://investor.scisparc.com. The
Company will deliver a hard copy of its annual report, including
its complete audited consolidated financial statements, free of
charge, to its shareholders upon request to the Company’s investor
relations contact: IR@scisparc.com.
About SciSparc
(NASDAQ: SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the
treatment of Tourette syndrome and for the treatment of Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status
epilepticus.
Information on, or accessible through, the
websites mentioned above does not form part of this press
release.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other U.S.
federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses expanding its
intellectual property portfolio and targeting the discovery of new
potential drugs and advancement in its clinical and pre-clinical
programs to move closer towards developing and presenting
innovative therapies. Because such statements deal with future
events and are based on SciSparc's current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
including those discussed under the heading "Risk Factors" in
SciSparc's Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission (the "SEC") on April 28,
2022, and in subsequent filings with the SEC. Except as otherwise
required by law, SciSparc disclaims any intention or obligation to
update or revise any forward-looking statements, which speak only
as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
For more information, please contact:
IR@scisparc.comTel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024